Albireo Pharma, Inc. (NASDAQ: ALBO) announced today the pricing of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per share. Albireo's gross proceeds from this offering are expected to be approximately $40 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Albireo has granted the underwriters a 30-day option to purchase up to an additional 285,750 shares of common stock on the same terms and conditions. All of the shares in the offering are being sold by Albireo. The offering is expected to close on or about February 3, 2020, subject to customary closing conditions.
Jefferies is acting as the sole book-running manager and representative of the underwriters for the offering.